摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethanesulfonic acid (2-oxo-2-phenyl-ethyl)-amide | 546112-35-0

中文名称
——
中文别名
——
英文名称
ethanesulfonic acid (2-oxo-2-phenyl-ethyl)-amide
英文别名
2-(ethylsulfonylamino)acetophenone;N-phenacylethanesulfonamide
ethanesulfonic acid (2-oxo-2-phenyl-ethyl)-amide化学式
CAS
546112-35-0
化学式
C10H13NO3S
mdl
——
分子量
227.284
InChiKey
HYBDUKYZQWXPCI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    384.5±44.0 °C(Predicted)
  • 密度:
    1.236±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    15
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    71.6
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    ethanesulfonic acid (2-oxo-2-phenyl-ethyl)-amide苯胺过氧化二异丙苯sodium acetate 、 copper(II) acetate monohydrate 作用下, 以 乙酸乙酯 为溶剂, 反应 1.0h, 以60%的产率得到2-oxo-N,N',2-triphenylacetimidamide
    参考文献:
    名称:
    铜催化α-氨基酮化合物与胺的氧化交叉偶联合成2-氧代乙acet
    摘要:
    用于经由铜的2-氧代acetamidines合成的一般和有效的方法-催化的氧化胺与α氨基酮化合物的交叉偶联物来实现的。在该反应中,α-氨基酮的C-N键断裂,并且通过一次转化即可构建新的C-N和C N键。该反应体系具有广泛的底物范围,并提供了合成2-氧代-乙acet的简便途径。
    DOI:
    10.1016/j.catcom.2019.105766
  • 作为产物:
    描述:
    2-甲基喹啉二甲基亚砜 作用下, 以60%的产率得到ethanesulfonic acid (2-oxo-2-phenyl-ethyl)-amide
    参考文献:
    名称:
    2-甲基喹啉通过DMSO促进N-磺酰基氮丙啶的氧化开环:轻松合成α-氨基芳基酮
    摘要:
    已经开发了2-甲基喹啉用DMSO促进N-磺酰基氮丙啶的室温氧化开环,为合成各种不同的N-磺酰基保护的α-氨基芳基酮提供了一种温和而便捷的方法。2-甲基喹啉的使用对于这种温和转化的成功至关重要,并且可以实现良好的优良收率。
    DOI:
    10.1016/j.tet.2016.10.041
点击查看最新优质反应信息

文献信息

  • Thiadiazoline derivative
    申请人:Murakata Chikara
    公开号:US20060074113A1
    公开(公告)日:2006-04-06
    (wherein R 1 and R 4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R 5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R 2 represents —C(═W)R 6 or the like; R 3 represents a hydrogen atom, —C(═W A )R 6A , or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.
    提供了一种抗肿瘤剂,其中R1和R4相同或不同,每个代表氢原子,取代或未取代的低级烷基,取代或未取代的低级炔基,取代或未取代的低级烯基或类似物;R5代表取代或未取代的杂环基,取代或未取代的芳基或类似物;R2代表-C(═W)R6或类似物;R3代表氢原子,-C(═WA)R6A或类似物。该抗肿瘤剂包含由上述通式(I)表示的噻二唑啉衍生物或其药理学上可接受的盐作为活性成分。
  • THIADIAZOLINE DERIVATIVE
    申请人:MURAKATA Chikara
    公开号:US20080207706A1
    公开(公告)日:2008-08-28
    (wherein R 1 and R 4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R 5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R 2 represents —C(═W)R 6 or the like; R 3 represents a hydrogen atom, —C(═W A )R 6A , or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.
    提供了一种抗肿瘤剂,其包括由上述一般式(I)表示的噻二唑啉衍生物或其药学上可接受的盐作为活性成分,其中R1和R4相同或不同,每个代表氢原子,取代或未取代的低碳基,取代或未取代的低炔基,取代或未取代的低烯基或类似物; R5代表取代或未取代的杂环基,取代或未取代的芳基或类似物; R2代表-C(═W)R6或类似物; R3代表氢原子,-C(═WA)R6A或类似物。
  • Mitotic kinesin inhibitor
    申请人:Murakata Chikara
    公开号:US20070155804A1
    公开(公告)日:2007-07-05
    A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R 1 represents a hydrogen atom and the like, R 2 represents a hydrogen atom, —C(═W)R 6 (wherein W represents an oxygen atom or a sulfur atom, and R 6 represents substituted or unsubstituted lower alkyl and the like) and the like, R 3 represents —C(═Z)R 19 (wherein Z represents an oxygen atom or a sulfur atom, and R 19 represents substituted or unsubstituted lower alkyl and the like) and the like, R 4 represents substituted or unsubstituted lower alkyl and the like, and R 5 represents substituted or unsubstituted aryl and the like] and the like are provided.
    一种有丝分裂动力蛋白Eg5抑制剂,其包括由通式(I)表示的噻二唑衍生物或其药学上可接受的盐作为活性成分:[其中R1代表氢原子等,R2代表氢原子,-C(═W)R6(其中W代表氧原子或硫原子,R6代表取代或未取代的低级烷基等)等,R3代表-C(═Z)R19(其中Z代表氧原子或硫原子,R19代表取代或未取代的低级烷基等)等,R4代表取代或未取代的低级烷基等,R5代表取代或未取代的芳基等]等。
  • Mitotic Kinesin Inhibitor
    申请人:KATO Kazuhiko
    公开号:US20110275827A1
    公开(公告)日:2011-11-10
    A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R 1 represents a hydrogen atom and the like, R 2 represents a hydrogen atom, —C(═W)R 6 (wherein W represents an oxygen atom or a sulfur atom, and R 6 represents substituted or unsubstituted lower alkyl and the like) and the like, R 3 represents —C(═Z)R 19 (wherein Z represents an oxygen atom or a sulfur atom, and R 19 represents substituted or unsubstituted lower alkyl and the like) and the like, R 4 represents substituted or unsubstituted lower alkyl and the like, and R 5 represents substituted or unsubstituted aryl and the like] and the like are provided.
    一种有丝分裂动力蛋白Eg5抑制剂,该抑制剂包括由通式(I)所表示的噻二唑衍生物或其药学上可接受的盐作为活性成分:[其中R1表示氢原子等,R2表示氢原子,-C(═W)R6(其中W表示氧原子或硫原子,R6表示取代或未取代的低碳基等)等,R3表示-C(═Z)R19(其中Z表示氧原子或硫原子,R19表示取代或未取代的低碳基等)等,R4表示取代或未取代的低碳基等,R5表示取代或未取代的芳基等]等。
  • M-STAGE KINESIN INHIBITOR
    申请人:KYOWA HAKKO KOGYO CO., LTD.
    公开号:EP1616866A1
    公开(公告)日:2006-01-18
    A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, -C(=W)R6 (wherein W represents an oxygen atom or a sulfur atom, and R6 represents substituted or unsubstituted lower alkyl and the like) and the like, R3 represents -C(=Z)R19 (wherein Z represents an oxygen atom or a sulfur atom, and R19 represents substituted or unsubstituted lower alkyl and the like) and the like, R4 represents substituted or unsubstituted lower alkyl and the like, and R5 represents substituted or unsubstituted aryl and the like] and the like are provided.
    一种有丝分裂驱动蛋白 Eg5 抑制剂,其活性成分包括通式 (I) 所代表的噻二唑 啉衍生物或其药理学上可接受的盐: [其中 R1 代表氢原子等,R2 代表氢原子、-C(=W)R6(其中 W 代表氧原子或硫原子,R6 代表取代或未取代的低级烷基等)等,R3 代表-C(=Z)R19(其中 Z 代表氧原子或硫原子、R4代表取代或未取代的低级烷基等,R5代表取代或未取代的芳基等]等。
查看更多